Abstract: Human HSPA2 is a member of the HSPA (HSP70) family of heat-shock proteins, encoded by the gene originally described as testis-specific. Recently, it has been reported that HSPA2 can be also expressed in human somatic tissues in a cell-type specific manner. The aim of the present study was to find out whether HSPA2 can increase the resistance of somatic cells to the toxic effect of heat shock, proteasome inhibitors, and several anticancer cytostatics. We used a Chinese hamster fibroblast V79 cell line because these cells do not express the HSPA2 and cytoprotective HSPA1 proteins under normal culture conditions and show limited ability to express HSPA1 in response to heat shock and proteasome inhibitors. We established, by retroviral gene transfer, a stable V79/HSPA2 cell line, which constitutively overexpressed HSPA2 protein. The major observation of our study was that HSPA2 increased long-term survival of cells subjected to heat shock and proteasome inhibitors. We found, that HSPA2 confers resistance to bortezomib-induced apoptosis. Thus, we showed for the first time that in somatic cells HSPA2 can be a part of a system protecting cells against cytotoxic stimuli inducing proteotoxic stress.
Introduction
The HSPA2 gene belongs to the HSPA multigene family (previously called HSP70 (Kampinga et al. 2009 ) and has been initially characterized in rodents as testis-specific and highly active in pachytene spermatocytes (Krawczyk et al. 1988; Zakeri et al. 1988 ). Construction of HspA2 -/-knockout mice revealed that the lack of corresponding protein resulted in infertility of male mice caused by disturbances in the dissociation of the synaptonemal complex and malfunction of specific cyclin-dependent kinase (Zhu et al. 1997; Dix et al. 1997) .
Parallel studies led to the identification and cloning of the human HSPA2 gene (Bonnycastle et al. 1994) , which exhib-ited high expression in spermatocytes, spermatids, and in mature spermatozoa (Huszar et al. 2000) . Aberrant HSPA2 expression in human testes has been related to male infertility (Cedenho et al. 2006) . Although in samples derived from normal human tissues the highest mRNA level was detected in the testes, significant amounts of transcripts were also found in tissue specimens from various somatic organs (Bonnycastle et al. 1994) . Gene expression analysis at the protein level confirmed that in human somatic tissues HSPA2 was expressed in a cell-type specific manner (Scieglinska et al. 2011) . The highest level of HSPA2 was detected in cells of the basal layers of the skin, esophagus, and bronchus epithelia (Scieglinska et al. 2011) . However, the function of HSPA2 in somatic cells is so far unknown. The HSPA2 protein was also found in various human cancer cell lines (Rohde et al. 2005; Pigłowski et al. 2007; Scieglińska et al. 2008 ) and in some primary tumors (Scieglińska et al. 2008; Garg et al. 2010) . Silencing the expression of the HSPA2 gene by RNAi suggested that HSPA2 increases the growth rate and tumorigenic potential of cancer cells (Rohde et al. 2005; Garg et al. 2010) .
The human HSPA family includes several proteins sharing high similarity of their amino acid sequence. Six of them, including HSPA2 and stress-inducible cytoprotective HSPA1, are classified as cytosol/nuclear proteins able to translocate between the cytoplasm and nucleus (Kampinga et al. 2009 ). It is generally accepted that cytosol/nuclear HSPAs share a common characteristic of essentially nonselective chaperones, although some degree of functional differentiation between them was reported (Kampinga et al. 2009; Daugaard et al. 2007) . It seems that at least their general cytoprotective function can be species independent (Daugaard et al. 2007 ). This feature is best exemplified by observations that stress-inducible HSP70 from Drosophila protected mouse and monkey cells against heat shock (Pelham 1984) and that human inducible HSPA1 protected rat or hamster cells against heat shock and other insults (Oyake et al. 2006; Kabakov et al. 2002; Hut et al. 2005) . These findings indicate that heterologous expression systems are appropriate for studying a general cytoprotective function of human HSPA proteins.
The aim of the present study was to test whether HSPA2 protein can increase the resistance of somatic cells to the toxic effect of heat shock, proteasome inhibitors, and several anticancer cytostatics that affect the structure of DNA and microtubules. The study was performed using Chinese hamster fibroblasts V79 cell line, in which neither endogenous HSPA2 nor HSPA1 are synthesized under physiological conditions. By retroviral gene transfer we established a stable V79/HSPA2 cell line constitutively expressing human HSPA2 protein. Cells were subjected to cytotoxic stimuli and subsequently long-term survival was assessed by clonogenic assay. We found that HSPA2 protected cells against stimuli-inducing proteotoxic stress (heat shock and proteasome inhibitors). Specifically, HSPA2 was found to be an antiapoptotic factor in bortezomib-treated V79 cells.
Materials and methods

Recombinant plasmids
The human HSPA2 coding sequence was excised from the pEF1/HSPA2 plasmid (Scieglińska et al. 2008 ) by HindIII and SfuI restriction endonucleases. The pLNCX2/HSPA2 vector, encoding the HSPA2 protein, was constructed by inframe insertion of the HSPA2 coding sequence between HindIII and ClaI restriction sites of the pLNCX2 plasmid (Clontech, Mountain View, Calif.), placing it under the control of the CMV promoter. The sequence of the obtained vector was confirmed by direct sequencing using a BigDye Terminator v. 3.1 cycle sequencing kit (Applied Biosystem, Foster City, Calif.). All plasmids were purified using a QIAfilter plasmid kit (Qiagen, Hilden, Germany) in accordance with the manufacturer's instruction.
Establishment of the cell line stably overexpressing HSPA2 protein
Chinese hamster lung fibroblasts V79 (originally provided by Norbert H. Seemayer and stored in our cell bank) were cultured in Dulbecco's modified eagle medium (DMEM; Sigma-Aldrich, St Louis, Mo.) supplemented with 10% heatinactivated fetal bovine serum (MP Biomedicals, Illkirch, France) and 40 mg/mL gentamycin sulfate (Sigma-Aldrich) at 37°C in humidified 5% CO 2 atmosphere in T-25 flasks and subcultured for up to 20 passages.
The V79/HSPA2 cell line, which overexpresses HSPA2 protein, was established by retroviral transfer of the pLNCX2/HSPA2 plasmid. The V79/Neo control cell line was established by transfer of the pLNCX2 vector. Packaging cell line RetroPack PT67 (Clontech) was transfected with pLNCX2/HSPA2 and pLNCX2 plasmids, respectively, using Lipofectamine TM 2000 (Invitrogen Corp., Carlsbad, Calif.) in accordance with the manufacturer's protocol. After transfection, cells were grown in culture medium for 24 to 48 h and then G418 (0.5 mg/mL) was added to select stably transfected cells. Next, viral supernatants were harvested, centrifuged to remove cellular debris (500g, 10 min), and filtered through a 0.44 µm pore size cellulose acetate filter. V79 cells were infected by 24 h incubation at 32°C with viral supernatants diluted (1:3 (v/v)) in growth medium supplemented with polybrene (8 µg/mL). Total pools of infected cells were selected in medium supplemented with G418 (0.5 mg/mL).
Protein extraction and Western blot analysis
To prepare total protein extracts cells were cultured in 60 mm dishes to~80% confluence. Then cells were lysed in 100 µL of buffer containing 50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 0.1% Nonidet P-40, 50 mmol/L NaF, 1 mmol/L DTT, 1 mmol/L PMSF, and protease inhibitor mixture (Complete™; Roche Applied Science, Basel, Switzerland). After incubation on ice (20 min), lysates were centrifuged (15 000g, 10 min) at 4°C and supernatants were aliquoted and stored at -80°C. Total protein content was determined using a Protein Assay kit (BioRad Laboratories), and 20-50 µg of proteins were fractionated by SDS-PAGE on 8% polyacrylamide gels and blotted onto a nitrocellulose membrane (Protran®, Whatman GmbH, Dassel, Germany), blocked (60 min) in 5% skimmed milk-TTBS (0.25 mol/L Tris-HCl (pH 7.5), 0.15 mol/L NaCl, 0.1% Tween-20), and incubated overnight (4°C) with primary antibody. The following antibodies were used: anti-HSPA2 (Scieglińska et al. 2008 (Scieglińska et al. , 2011 , anti-HSPA1 (SPA810, StressGen Biotechnology, Victoria, B.C.), anti-caspase-9 and anti-caspase-3 (Cell Signaling Technology, Danvers, Mass.), anti-HSPA8 (Santa Cruz Biotechnology Inc., Santa Cruz, Calif.), and anti-b-actin (Chemicon, Hampshire, UK). Primary antibodies were detected by a Vectastain ABC kit (Vector Laboratories Inc., Burlingame, Calif.) and 3,3′-diaminobenzidine or by goat antimouse horseradish peroxidase conjugated secondary antibody (Thermo Scientific Pierce, Rockford, Ill.) and visualized using SuperSignal® West Pico Chemiluminescent Substrate kits (Pierce Biotechnology, Rockford, Ill.).
Immunocytochemistry
For immunocytochemistry, cells were grown in 4-well Lab-Tek permanox chamber slides (Nalgene Nunc International), fixed with methanol (2 min, -20°C), washed with phosphate buffered saline (PBS), blotted in 1% NGS, and incubated overnight with anti-HSPA2 primary antibody. Immunoreaction was detected using biotinylated secondary antibody, an avidin-biotin complex (ABC Vectastain kit; Vector Laboratories Inc.), and 3,3′-diaminobenzidine as a chromogen. Counterstaining was done with hematoxylin. Cells were observed using an ECLIPSE E800 (Nikon) microscope. Pictures were acquired with a Hamamatsu CCD camera and image analysis system (Lucia).
Clonogenic assay
Cells were seeded (500 per 60 mm plate, Nunc) and allowed to grow for 24 h. The next day, cells were treated for 24 h with cytotoxic compounds dissolved in the culture medium. Except bortezomib, all drugs were purchased from Sigma-Aldrich and were used at the following concentrations: paclitaxel, 10 and 50 nmol/L; vinblastine, 0.5 and 1.0 nmol/L; doxorubicin, 20, 30, and 40 nmol/L; and MG132, 250, 350, 650, and 750 nmol/L. Bortezomib was purchased from Selleck Chemicals LLC (Houston, Tex.) and used at concentrations of 20, 30, 40, and 50 nmol/L. Heat shock was induced by the addition of prewarmed (43-45°C) growth medium to cells grown on culture dishes, followed by incubation in a CO 2 incubator (1 h, 43-45°C). After treatment, the culture medium was replaced by a fresh one and cells were grown for 5 days. Colonies were washed with PBS, fixed with methanol, stained with 5% Giemsa in PBS, and counted.
Flow cytometry
Cells were seeded onto 60 mm plates at density of 2 × 10 5 cells/well and allowed to attach for 24 h. Next, cells were treated for 12 and 24 h with bortezomib (50 nmol/L), paclitaxel (50 nmol/L), and vinblastine (1 nmol/L). Then cells (both floating and adherent) were harvested, washed with PBS, fixed with 70% ethanol (-20°C), incubated with RNase A (100 µg/mL), and stained using propidium iodide (PI; 100 mg/mL). For the PI exclusion test, unfixed cells were stained (PI concentration 1 mg/mL). Stained cells (10 000) were analyzed for red fluorescence in a FACSCanto flow cytometer (BD Bioscience, San Jose, Calif.). A blue laser (488 nm) for excitation and PE channel (585/42 nm) for detection of PI fluorescence were used.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay and mitotic index analysis
Cells were seeded onto 24-well plates at density of 2 × 10 4 cells/well. The next day, cells were treated for 24 h with bortezomib (50 nmol/L). Then, cells were harvested (both floating and adherent), washed with PBS, and spun onto the glass slides using a cytocentrifuge Cytospin 3 (Shandon, Pittsburgh, Pa.). For the TUNEL assay, cells were fixed with 4% paraformaldehyde and permeabilized at 0°C with 0.1% Triton-X 100 and 0.1% sodium citrate in PBS. Next, cells were washed with PBS, incubated with premixed TUNEL reagents (Roche Applied Science) in accordance with the manufacturer's protocol, washed with PBS, and stained with 1 µg/mL DAPI solution. For the mitotic index analysis, bortezomibtreated cells were harvested (both floating and adherent), cytospun, fixed with methanol, and stained with 1 µg/mL DAPI solution. The mitotic index was calculated by counting mitotic cells and expressed as a percent of mitotic vs. total cells count. At least 1000 cells were counted per slide.
Statistical analysis
Statistically significant differences observed in drug-treated versus control cultures were determined using a Student's t test. The level of significance was set at p < 0.05.
Results and discussion
Cell lines of human origin usually express significant levels of HSPA1 (Calderwood et al. 2006) , which is commonly accepted as a potent cytoprotective agent (Calderwood et al. 2006; Calderwood and Ciocca 2008) . This could pose a serious drawback, limiting evaluation of HSPA2 activity, because its potential cytoprotective function could be masked by HSPA1. Therefore, we decided to perform experiments using a cell line of rodent origin. We chose a Chinese hamster lung fibroblast V79 cell line, because these cells did not express endogenous HSPA2 and, most importantly, HSPA1 under normal culture conditions (Fig. 1A) . Additionally, these cells have proven a suitable model for studies of toxicity, mutagenicity, and DNA repair (Chaung et al. 1997; Glowala et al. 2002) .
To study the cytoprotective function of HSPA2 we established a V79 cell line stably overexpressing HSPA2 protein ( Figs. 1A and 1B) . The V79/HSPA2 cell line was created using a retroviral gene delivery system to integrate the pLNCX/HSPA2 vector, coding for HSPA2 protein, into the V79 genome. We also established, by retroviral delivery of the pLNCX vector, a control V79/Neo cell line that expressed only the neomycin-resistance gene. In V79/HSPA2 cells, the level of HSPA2 expression was high (Figs. 1A and 1B) and remained stable over multiple passages. The HSPA2 expression influenced neither the morphology or proliferation rate of V79/HSPA2 cells (not shown) nor the levels of other cytoplasmic members of the HSPA family (Fig. 1A) .
To determine whether HSPA2 can act as a cytoprotective agent we exposed V79/HSPA2 and control V79/Neo cells to hyperthermia, proteasome inhibitors (MG132 and bortezomib), microtubule-affecting drugs (vinblastine and paclitaxel), and DNA-intercalating topoisomerase II inhibitor (doxorubicin). Then, we performed a colony-forming assay to assess the proliferation potential of treated versus untreated cells. We found that the HSPA2 increased the viability of cells exposed to heat shock and proteasome inhibitors (Fig. 2) , without affecting the survival of cells exposed to other treatments (not shown). We observed a reduction in clonogenic potential of V79 cells treated for 1 h with hyperthermia at 43 and 44°C ( Fig. 2A) . At 44°C, the colony formation of V79/Neo cells was severely reduced whereas clonogenic potential of V79/HSPA2 cells was significantly higher (51% vs. 82.5% of the control; p = 0.022). Similarly, dose-dependent reduction in the clonogenic potential of V79 cells was observed following exposure to proteasome inhibitors (Figs. 2B and 2C) . The colony-formation rate of V79/HSPA2 cells was significantly higher than in the control V79/Neo cells (Figs. 2C and 2F) after treatment with bortezomib (at concentrations 30 and 40 nmol/L) and with MG132 (at concentrations 500, 650, and 750 nmol/L). The higher clonogenic potential of bortezomib-treated V79/HSPA2 cells was accompanied by their lower mortality in short-term PI exclusion tests (Fig. 2D) . By 24 h of the bortezomib treatment at concentrations of 40 and 50 nmol/L, followed by 24 h recovery, viable cell counts of V79/HSPA2 cells were significantly higher than in the control V79/Neo cells (p < 0.05).
It is widely known that heat shock and other various stressful stimuli can highly activate expression of the HSPA1 protein (Kampinga et al. 2009; Daugaard et al. 2007 ). The expression of the HSPA2 gene is not induced by heat shock because of a lack of the functional HSE regulatory element in its promoter. However, in response to hyperthermia, HSPA2 protein translocates from the cytoplasm into the nucleus and accumulates in centrosomes and nucleoli (Sciegliń-ska et al. 2008) . Members of the HSPA family, mainly HSPA1 protein, can be a part of multi-protein system influencing the sensitivity/resistance of normal and neoplastic cells to hyperthermia, bortezomib, and other stressful stimuli (Chauhan et al. 2003 , Shringarpure et al. 2006 Calvaruso et al. 2007; Sarközi et al. 2008; Combaret et al. 2008; Kumar and Rajkumar 2008; Bonner et al. 2010; Daugaard et al. 2007 ). Thus, it was important to establish whether increased resistance of V79/HSPA2 cells to hyperthermia and bortezomib was due to the introduction of the HSPA2 protein or rather due to the induction of endogenous HSPA1 expression. Figure 2E shows that in V79 cells the expression of HSPA1 was activated only under a lethal heat shock condition (45°C). Although it was reported that proteasome inhibitors can induce expression of HSPA1 (Calvaruso et al. 2007; Shringarpure et al. 2006; Sarközi et al. 2008; Bonner et al. 2010) , this protein was not detected in bortezomib-treated V79 cells, even following administration of high drug doses (Fig. 2F) . Weak and transient activation of HSPA1 was detected in cells shortly treated with MG132 only (Fig. 2G) . These results indicated that V79 cells were relatively resistant to hyperthermia-and proteasome inhibitors-induced activation of HSPA1 expression. Thus, the use of V79 cells eliminated the need for downregulation of the HSPA1 protein level in order to undoubtedly state that better survival of V79/HSPA2 cells exposed to hyperthermia and bortezomib is dependent on cytoprotective activity of HSPA2.
Bortezomib is a boronic acid dipeptide, the first proteasome inhibitor approved as an anticancer drug (reviewed in: Kumar and Rajkumar 2008; Chen et al. 2011; Crawford et al. 2011) . It reversibly binds the 20S proteasome and inhibits its proteolytic activity. Bortezomib also induces endoplasmic reticulum stress by interfering with the phosphorylation of double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase PERK, what enables hypophosphorylation of elongation initiation factor EIF2A and results in continuation of protein translation (Nawrocki et al. 2005) . Accumulation of garbage proteins, due to an overloaded endoplasmic-reticulum-associated degradation (ERAD) system and decreased activity of an ubiquitin-proteasome system, leads to proteotoxicity and induction of apoptotic cell death (Kumar and Rajkumar 2008; Chen et al. 2011; Crawford et al. 2011) . Although treatment with bortezomib seems to affect multiple cellular processes, upregulation of proapoptotic protein NOXA and suppression of NF-kB signaling are indicated as the major mechanisms of its anticancer activity (Chen et al. 2011; Crawford et al. 2011) . Malignant cells may develop several mechanisms to overcome the effects of proteasome inhibition. These include alterations in the structure of the proteasome complex, activation of alternate mechanisms of protein degradation, or modulation of cell signaling pathways that are affected by proteasome inhibition (Kumar and Rajkumar 2008) . Upregulation of heat shock protein expression was identified as one of the mechanisms of bortezomib resistance. In bortezomib-resistant human cells originating from various carcinomas and hematopoietic malignancies, upregulation and (or) stabilization of HSPB1 (HSP27) (Shringarpure et al. 2006; Chauhan et al. 2003; Combaret et al. 2008) , HSPA1 (Shringarpure et al. 2006; Calvaruso et al. 2007 ) and HSPC (HSP90) (Chauhan et al. 2003) were detected. Also, in normal human cells, upregulation of HSPs was found to be a part of a prosurvival response to bortezomib treatment (Sarközi et al. 2008 ; Bonner et al. 2010). However, HSPA2 has so far not been indicated as a factor influencing a cells response to bortezomib. Here, we find that HSPA2 increased cell viability in short-and longterm survival assays after treatment with this drug.
It is known that bortezomib induces cell-cycle arrest at the G2/M block leading to activation of proapoptotic signaling (Chen et al. 2011; Crawford et al. 2011) . Flow cytometry analysis (Fig. 3 ) revealed significant time-dependent and cell-line-specific differences in the cell-cycle distribution of V79/Neo and V79/HSPA2 cells after treatment with bortezomib at a concentration of 50 nmol/L (concentration near the IC 50 value determined by an MTT test for V79 cells; not shown). After 12 h of treatment, no essential differences were observed. In both cell lines a marked G2/M arrest occurred (22.2% and 23.5% at 0 nmol/L and 44.2% and 43.3% at 50 nmol/L, respectively). After 24 h of exposure, the G2/M block was still apparent in V79/HSPA2 cells, whereas in control cells the fraction of G2/M cells decreased (39.4% vs. 21%; p = 0.001). To further explore the effect of bortezomib on G2/M arrest we calculated the mitotic index. We did not find any differences in the number of mitoses in V79/Neo and V79/HSPA2 cells before and during bortezomib exposure (not shown). Altogether, these results clearly show that the observed G2/M block corresponds in fact to the arrest in G2 phase. Thus, it may be concluded that the overexpression of HSPA2 leads to the prolonged cell-cycle arrest at the G2 phase.
Additionally, after 24 h of the bortezomib treatment, we observed an increase in the number of subG1 cells in both cell lines; however, in V79/HSPA2 cells, this rise was significantly lower than in control cells (35.1% vs. 57.2%; p = 0.032; Fig. 3 ). Significant differences in the percent of subG1 cells between V79/Neo and V79/HSPA2 lines (Figs. 3A and 3B) suggested varying levels of bortezomibinduced apoptoses. By performing Western blot analysis we found that in bortezomib-treated V79/HSPA2 and V79/Neo cells (24 h, 50 nmol/L) the active forms of caspase 9 and caspase 3 are present (Fig. 4A) . Although no differences in the levels of active caspases were detected, we revealed by the TUNEL assay (Figs. 4B and 4C ) that a percent of TUNEL-positive apoptotic cells was lower in V79/HSPA2 cells as compared with V79/Neo cells (50 nmol/L: 24.7% vs. 42%; p = 0.007). These results indicate that HSPA2 is able to decrease the rate of bortezomib-induced apoptosis.
To summarize, we have shown here for the first time that the HSPA2 increased resistance of cells subjected to heat shock and to proteasome inhibitors, both treatments known to induce proteotoxic stress. Our results also indicate that HSPA2 reduced the level of apoptotic cells and this corresponded to more cells arrested in G2 phase of the cell cycle. These observations may suggest that HSPA2 protects G2-phase arrested cells against bortezomib-induced apoptosis.
Because of many various signaling pathways affected by bortezomib, we are not able to indicate the particular mechanism responsible for antiapoptotic activity of HSPA2. Nevertheless, it goes without saying that HSPA2 exhibits a prosurvival activity, similarly as the stress-inducible HSPA1 chaperone. This observation correlates well with the recently published data indicating that both HSPA2 and HSPA1 assisted refolding of denatured luciferase as well as suppressed its heat-shock-induced aggregation (Hageman et al. 2011) . Together, these findings may be relevant in view of recent observations that in human somatic tissues HSPA2 is expressed in specific cell types and that the patterns of HSPA2 and HSPA1 expression differ significantly (Scieglinska et al. 2011) . While no specific functions have been ascribed to HSPA2 in somatic cells so far, our observation, together with data showing that HSPA2 and HSPA1 share similar properties (Hageman et al. 2011) , is an important step in searching for the role of this protein in normal cells. Thus, it seems reasonable to conclude that HSPA2 may function in somatic cells as an important element of the cytoprotective system, reducing the level of proteotoxicity.
